Search Results

Jeffrey J. Popma, MD, to Join Medtronic

May 18, 2020—Medtronic announced that Jeffrey J. Popma, MD, will join the company as Vice President and Chief Medical Officer supporting the coronary, renal denervation, and structural heart businesses at Medtronic. Dr. Popma will officially assume his role with Medtronic on June 22, 2020, reporting to Nina Goodheart, President of the Coronary & Structural Heart division, which is part of the Cardiac and Vascular Group.

Results Published From CoreValve US Pivotal Trial

March 19, 2014—Jeffrey J. Popma, MD, et al published findings from the CoreValve US Pivotal Trial of the self-expanding CoreValve bioprosthesis (Medtronic, Inc., Minneapolis, MN). The study is available online ahead of print in the Journal of the American College of Cardiology.

Medtronic's CoreValve US Pivotal Trial Results Presented at TCT

October 29, 2013—Medtronic, Inc. (Minneapolis, MN) announced that coprincipal investigator Jeffrey J. Popma, MD, presented the results from the CoreValve United States pivotal trial at a late-breaking clinical trial session of the TCT 2013: Transcatheter Cardiovascular Therapeutics conference in San Francisco, California. These are the first United States data on Medtronic's self-expanding CoreValve transcatheter aortic valve replacement (TAVR) system.

PROTECT III Data Presented for Abiomed's Impella 2.5 and CP Devices for High-Risk PCI

September 26, 2019—Abiomed, Inc. announced that results from the PROTECT III study, an ongoing, prospective, single-arm FDA postapproval study for postmarket approval of the company’s Impella 2.5 and Impella CP devices for use in high-risk percutaneous coronary intervention (PCI) were presented by Jeffrey J. Popma, MD, at the 31st Transcatheter Cardiovascular Therapeutics (TCT) conference held September 25–29, in San Francisco, California. Dr. Popma is Director of Interventional Cardiology Clinical Services at Beth Israel Deaconess Medical Center, in Boston, Massachusetts, and a member of the study’s steering committee.

Two-Year EVOLUT Data Support TAVR in Low-Risk Patients

March 16, 2019—At the American College of Cardiology's (ACC) 68th Annual Scientific Session, being held March 16–18 in New Orleans, Louisiana, the 24-month findings from the EVOLUT Low-Risk trial will be presented on March 17 by senior investigator Michael J. Reardon, MD. The trial is comparing self-expanding transcatheter aortic valve replacement (TAVR) to surgical aortic valve replacement (SAVR) in patients at low surgical risk. The study, which was funded by Medtronic, used three of the company's devices (CoreValve, Evolut R, Evolut Pro) in the TAVR arm.

FDA Approves Low-Risk Indication for Medtronic's Evolut TAVR System

August 16, 2019–Medtronic announced FDA approval of the company's Evolut transcatheter aortic valve replacement (TAVR) system for patients with symptomatic severe native aortic stenosis who are at a low risk of surgical mortality.

FDA Approves Study of Medtronic's TAVR System in Low-Risk Patients With Bicuspid Aortic Valves

September 20, 2018—Medtronic announced that the FDA has approved an investigational device exemption to initiate a single-arm study to evaluate the CoreValve Evolut transcatheter aortic valve replacement (TAVR) system in patients with bicuspid aortic valves who are at low risk of surgical mortality.

Medtronic Evolut TAVR System Receives Approval for Low-Risk Indication in Europe

June 22, 2020—Medtronic announced CE Mark approval and the European launch of the Evolut system for transcatheter aortic valve replacement (TAVR) in patients with severe native aortic stenosis who are at a low risk of surgical mortality.

Extreme-Risk Patient Enrollment Completed in Medtronic's CoreValve US Pivotal Trial

January 24, 2012—Medtronic, Inc. (Minneapolis, MN) announced that it has completed patient enrollment for the extreme-risk study in its CoreValve US pivotal trial.

FDA Approves Medtronic's CoreValve TAVR System

January 17, 2014—Medtronic, Inc. (Minneapolis, MN) announced the US Food and Drug Administration (FDA) approval of the self-expanding transcatheter CoreValve system for patients with severe aortic stenosis who are too ill or frail to have their aortic valves replaced surgically.

Medtronic Presents Data on Evolut Pro TAVR System

November 6, 2017—Medtronic announced that new data for the company's CoreValve Evolut transcatheter aortic valve replacement (TAVR) platform were presented at TCT 2017, the 29th annual Transcatheter Cardiovascular Therapeutics scientific symposium held October 30 to November 2 in Denver, Colorado.

United States Clinical Study Begins For Medtronic's CoreValve Evolut R Recapturable TAVR System

September 10, 2014—Medtronic, Inc. announced the first procedures in the United States in the CoreValve Evolut R clinical study.

US Pivotal Trial Shows Medtronic's CoreValve TAVR System Is Superior to Surgery in High-Risk Patients at 1 Year

March 29, 2014—Medtronic, Inc. (Minneapolis, MN) announced that the company’s CoreValve system for transcatheter aortic valve replacement (TAVR) showed results that are superior to surgical aortic valve replacement (SAVR) at 1 year in the High Risk Study of its CoreValve United States Pivotal trial, which evaluated patients with severe aortic stenosis who are considered high risk for surgery. 

Three-Year Data Presented From Medtronic Evolut Low Risk Trial of TAVR Versus SAVR

March 5, 2023—The American College of Cardiology (ACC) announced that the Evolut Low Risk trial demonstrated that the number of deaths and disabling strokes among patients at low surgical risk who were treated with transcatheter aortic valve replacement (TAVR) remained lower at 3 years postprocedure, but not significantly lower, compared with patients who received surgical aortic valve replacement (SAVR).